Search PubMed⌕ Search

Biomedical subjects

P Hauri

Publications and source records attributed to P Hauri.

At least 37 records · Page 2Linked to original sources
PubMed1981

Treating psychophysiologic insomnia with biofeedback.

After evaluating 165 insomniacs, 48 psychophysiologic insomniacs were randomly assigned to one of the following four groups: electromyographic (EMG) feedback, combined EMG and theta feedback, sensorimotor rhythm (SMR) feedback, and no treatment (control). Sleep evaluations by home logs and in the laboratory were done before and after biofeedback and nine months later. No feedback group showed improved sleep significantly more than did the controls. The amount of feedback learning correlated significantly with sleep improvement for the SMR group but not for the other groups. Initial tension of the insomniacs correlated positively with sleep improvement for the EMG group, but negatively with sleep improvement for the SMR group. Those treated with the biofeedback that seemed appropriate for their specific deficiencies showed significant sleep improvements, while those who received inappropriate feedback did not. Appropriate biofeedback methods may be effective for specific types of insomnia, but these procedures offer no panacea for all poor sleep.

Biofeedback, Psychology↗
PubMed1980

Childhood-onset insomnia.

Twenty patients who had been insomniac since childhood were compared with 39 who had become insomniac during adult life. The childhood-onset insomniacs took longer to fall asleep, slept less, and showed excessive amounts of REM sleep without eye movements. Adult-onset insomniacs showed more restless sleep. No differences between childhood- and adult-onset groups were found on personality inventories, but those with childhood-onset insomnia reported more evidence of possible "soft" neurological impairment.

Adult↗
PubMed1980

Idiopathic hypoventilation syndrome: importance of preventing nocturnal hypoxemia and hypercapnia.

This report describes a young woman with unexplained chronic hypoventilation that was greatly exacerbated during sleep. Treatment with nocturnal O2 during a 2-yr period was associated with stable cardiovascular function but severe morning headaches and lethargy, presumably related to nightly bouts of hypercapnia and acidosis during sleep. A subsequent 2-yr period in which ventilation was assisted during sleep by means of a rocking bed, but supplementary O2 was not used, was associated with disappearance of the headaches and improved psychosocial function, but with the insidious development of signs of pulmonary hypertension and right ventricular hypertrophy. This patient's clinical course demonstrates the separate adverse effects of intermittent hypoxemia and hypercapnia and emphasizes the importance of preventing both hypoxemia and hypercapnia during sleep.

Adult↗
PubMed1976

Effectiveness of intermediate-term use of secobarbital.

Secobarbital, 100 mg, was evaluated in two separate sleep laboratory drug evaluation studies, each with 4 insomniac patients. In both studies, the effect of secobarbital in inducing and maintaining sleep was evaluated, as well as the effects of the drug on sleep stages. Statistical analysis demonstrated that the results of the two studies could be combined. With short-term drug administration of secobarbital (up to 3 nights), there was an improvement in both sleep induction and sleep maintenance. Total wake time was decreased 43% below baseline and was consistently decreased in each third of the night. With intermediate-term drug administration (2 wk), total wake time was decreased only 14% (not statistically significant). Following drug withdrawal, the degree of sleep difficulty returned to baseline levels. The results indicate that secobarbital 100 mg is effective for short-term use but loses much of its effectiveness with intermediate use and suggest that the drug is of limited value for insomniac patients who require nightly medication beyond a period of 1 wk. With short-term administration, secobarbital induced a slight decrease in rapid eye movement (REM) and slow-wave sleep and a significant increase in stage 2 sleep. With intermediate administration, sleep stage values were similar to baseline levels. Following withdrawal, there was only a minimal increase in REM sleep above baseline levels, a significant increase in stage 3 sleep, and a significant decrease in stage 2 sleep. The rebound increase in stage 3 sleep is similar to that reported following withdrawal of pentobarbital.

Adult↗